GE Healthcare Life Sciences Hosts Graduate Students from Japan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GE Healthcare Life Sciences Hosts Graduate Students from Japan



GE Healthcare Life Sciences has formed a joint program with Osaka University to offer students access to GE Healthcare’s training and technologies for biopharmaceutical research and manufacturing, to help support future growth of the sector in Japan.  The program, Interdisciplinary Program for Biomedical Sciences (IPBS), is Osaka University’s government-funded commitment to graduate education, which aligns with GE Healthcare Japan’s “Life Sciences Academy,” a GE Healthcare initiative launched in April 2013 with the objective of supporting the development of life sciences researchers in Japan.  Of the 14 IPBS graduate students, four will visit GE Healthcare Life Science’s Uppsala site for three weeks.

While at GE Healthcare in Uppsala, the Osaka University students will experience life in an R&D laboratory, closely working with GE Healthcare scientists and engineers. The students will receive comprehensive training in GE Healthcare’s advanced bioprocessing technologies and gain experience of protein interaction analysis and laboratory-scale protein purification using GE Healthcare instruments including Biacore and MicroCal systems for label-free analyses and ÄKTA pure chromatography systems.

Source: GE Healthcare Life Sciences

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here